Athena and its supporters have asked the Supreme Court to clarify patent eligibility, but Mayo recently countered that this is a job for legislators.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
The consortium is comprised of researchers from Inova, Roswell Park Comprehensive Cancer Center, the Mayo Clinic, and MD Anderson Cancer Center.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The group believes that being able to track ctDNA changes down to the lowest possible levels may be necessary for liquid biopsy to monitor treatment in early-stage cancers.
The partners are working under NIAAA grants to identify genetic markers to help predict response to the drug acamprosate, which is used as a treatment for alcoholism.
The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.
Researchers are sampling the wild relatives of modern crops to try to preserve genetic diversity, NPR reports.
MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.
Undark reports on a bill introduced this year to the US House of Representatives to strengthen scientific integrity.
In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.